Aligos Therapeutics (ALGS) vs Jasper Therapeutics (JSPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Jasper Therapeutics (JSPR) has outperformed Aligos Therapeutics (ALGS) over the past year, gaining 411.2% versus a loss of 86.8%. Over five years, JSPR leads with a -89.4% price change compared with -99.7% for ALGS. Jasper Therapeutics is the larger company by market cap ($9.6 million vs $7.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALGS | JSPR |
|---|---|---|
| Share price | $1.22 | $8.69 |
| Market cap | $7.62M | $9.64M |
| 1-day change | -2.40% | -18.25% |
| YTD return | -86.91% | +374.86% |
| 1-year return | -86.75% | +411.18% |
| 5-year return | -99.70% | -89.44% |
| EPS (TTM) | $-6.46 | $-7.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.19M | — |
| Revenue growth (YoY) | -39.46% | — |
| Net income (latest FY) | $-24.19M | $-75.80M |
| Operating margin | -4024.93% | — |
| Net margin | -1106.72% | — |
| 52-week high | $13.69 | $72.60 |
| 52-week low | $1.18 | $8.47 |
| Distance from 52-week high | -91.09% | -88.03% |
| Analyst consensus | none | none |
| Avg. price target upside | +4193.44% | +130.15% |
| Average volume | 57.37K | 16.89K |
| Shares outstanding | 5.45M | 1.11M |
| Employees | 82 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JSPR has outperformed ALGS by 497.9 percentage points over the past year.
About Aligos Therapeutics
ALGS stock →Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
About Jasper Therapeutics
JSPR stock →Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
ALGS vs JSPR FAQ
Which is bigger, Aligos Therapeutics or Jasper Therapeutics?
Jasper Therapeutics (JSPR) is larger, with a market capitalization of $9.64M compared with $7.62M for Aligos Therapeutics (ALGS).
Which stock has performed better over the past year, ALGS or JSPR?
JSPR returned +411.18% over the past 12 months, compared with -86.75% for ALGS (price return, excluding dividends). Past performance does not predict future results.
Are Aligos Therapeutics and Jasper Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.